Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

metastatic hormone-sensitive prostate cancer

Bayer symbol

Bayer drug cuts infusion burden in haemophilia A

Able to provide longer-term protection against bleeding episodes in late-stage trial

- PMLiVE

MHRA announces senior appointment

Neil McGuire joins as clinical director of medical devices

- PMLiVE

FDA knocks back J&J and Bayer’s Xarelto in ACS

Follows unanimous negative committee vote

- PMLiVE

GSK’s diabetes drug among CHMP recommendations

EMA committee also backs drugs from Bayer, Takeda and Linepharma France

- PMLiVE

Xarelto should not be approved in ACS says FDA panel

Advisory committee votes against new indication for Bayer and J&J’s anticoagulant

Bayer symbol

Bayer and Regeneron to develop second wet AMD therapy

Will collaborate on drug to be used in combination with Eylea

Bayer symbol

Bayer establishes research centre in Beijing

Pharma company will collaborate on cardiology, oncology, haematology and gynaecology projects

Bayer symbol

Bayer agrees $2.9bn deal for Algeta to get Xofigo control

Raises initial offer to buy Norweigan pharma company

EU flag

EU discusses action on stroke prevention

Stakeholders meet at European Parliament

Bayer symbol

Bayer offers $2.4bn to buy Xofigo partner Algeta

Norwegian firm says negotiations still at 'an early stage'

- PMLiVE

Nexavar cleared for thyroid cancer by FDA

Bayer and Onyx win expansion of oncology drug’s use in US

Bayer symbol

EU approval for Bayer’s prostate cancer drug

Xofigo wins marketing authorisation from European Commission

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links